Overview

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Myovant Sciences GmbH
Treatments:
Relugolix